Company news
Personalis, Inc. news in 2022
Personalis, Inc.'s news releases, calls and decks from 2022, newest first.
Personalis Announces CEO Retirement and Transition
December 13, 2022
Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
November 29, 2022
Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference
November 20, 2022
Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 6, 2022
Personalis Reports Third Quarter 2022 Financial Results
November 1, 2022
Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business
October 30, 2022
Personalis to Announce Third Quarter 2022 Financial Results
October 18, 2022
Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer
October 3, 2022
Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
August 29, 2022
Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics
August 16, 2022
Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
August 14, 2022
Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
August 3, 2022
Personalis Reports Second Quarter 2022 Financial Results
August 2, 2022
Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics
August 1, 2022
Personalis to Announce Second Quarter 2022 Financial Results
July 19, 2022
Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease
July 11, 2022
Personalis Reports First Quarter 2022 Financial Results
May 3, 2022
Personalis to Present at Upcoming Investor Conferences
April 27, 2022
Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
April 25, 2022
Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales
April 20, 2022
Personalis to Announce First Quarter 2022 Financial Results
April 19, 2022
Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene
April 11, 2022
Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform
April 11, 2022
Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022
April 10, 2022
Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference
March 30, 2022
Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors
March 23, 2022
Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022
March 22, 2022
Personalis Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
Personalis to Present at the Cowen 42nd Annual Health Care Conference
February 22, 2022
Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection
February 14, 2022
Personalis to Announce Fourth Quarter and Full-Year Financial Results
February 9, 2022
Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 31, 2022
Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
January 5, 2022